Melanoma is generally recognized as one of the types of cancer that have an increasing coverage, although it is usually diagnosed in the early stages. In recently, the ways of melanoma treatment in patients with metastatic diseases were so limited that many patients were practically doomed to failure.have developed melanoma therapeutic agents in the past ten years due to the use of immune checkpoint inhibitors. Now people with levels II and III can easily have a long remission duration. Throughout, modern options for melanoma treatment as the source of hope for numerous people serve.
In fact, innovations in the field of melanoma treatment are associated with the use of checkpoint inhibitors and the so-called adjuvant therapy./MEK inhibitors for patients with BRAF-V600 mutations significantly expanded survival and enables some patients to remain in the event of a permanent disease of the therapy. "(Poklepovic & Luke, 2019, p. 1166).So-called "risk patients" with stage IIA through IIC melanoma, as Mr. B., can have long remission from this question about receiving a special course.
Nevertheless, patients in remission with adjuvant therapies should remain better.Connected toxicity of this interferon and other treatments such as the anti-CTLA4 antibody ipilimumab ‚Äù(Jenkins & Fisher, 2021, p. 27). So it was for many efficient doctors from little trust. In reference to stage II, it requires the lower incidence of theProgress of diseases an unprecedented effectiveness (Rozeman et al., 2018). However, adjuvant therapies in the field of cancer treatment have been recognized with time. The case of Mr. B can be the one in which adjuvant therapy could have prevented the biopsyBiopsy returns to melanoma in stage II.